Data as of Q4 2025 (Dec 31, 2025)

Affinity Asset Advisors, LLC

โ€ขCIK: 1773195โ€ขFiling: Q4 2025

**Affinity Asset Advisors, LLC** manages $1.7B across a diversified portfolio of 92 positions. The fund exhibits significant concentration in sector-specific and thematic plays, highlighted by a top holding in XBI at $182.9M. Further notable allocations include substantial positions in APGE ($93.2M) and IM8N ($78.3M). This structure suggests a tactical, high-conviction approach targeting specific market segments.

Total AUM
$1.3B
+ $299.9M in options
QoQ Performance
+27.0%
Positions
80
+ 7 options
Top 10 Concentration
46.5%
Latest Filing
Q4 2025

Top Holdings Allocation

XBI
APGE
XBI11.2%
APGE5.7%
IM8N4.8%
ABVX4.2%
IBB4.1%
VTYXUSD3.6%
XENE3.4%
PRAX3.4%

๐Ÿ“ˆ Biggest Buys

XBIPUT
SPDR SERIES TRUST
NEW
11.2% of portfolio
IBBCALL
ISHARES TR
NEW
4.1% of portfolio
PRAX
PRAXIS PRECISION MEDICINES I
NEW
3.4% of portfolio
XLVCALL
SELECT SECTOR SPDR TR
NEW
2.4% of portfolio
CYTK
CYTOKINETICS INC
+128.6%
3.1% of portfolio

๐Ÿ“‰ Biggest Sells

MDGL
MADRIGAL PHARMACEUTICALS INC
-72.9%
1.1% of portfolio
CNTA
CENTESSA PHARMACEUTICALS PLC
-45.8%
0.9% of portfolio
TRVI
TREVI THERAPEUTICS INC
-23.2%
1.7% of portfolio
ESTA
ESTABLISHMENT LABS HLDGS INC
-35.5%
0.9% of portfolio
TVTX
TRAVERE THERAPEUTICS INC
-40.0%
0.7% of portfolio

Sector Breakdown

Other99.8%
Healthcare0.2%

๐Ÿšช Exited Positionssold since Q3 2025

VRNA
VERONA PHARMA PLC
SOLD
$66.7M
SPY
SPDR S&P 500 ETF TR
SOLD
$56.3M
2GH
MERUS N V
SOLD
$26.9M
โ€”
PROTAGONIST THERAPEUTICS INC
SOLD
$14.7M
EX9
EXELIXIS INC
SOLD
$14.5M
+22 more exited positions

Changes from Q3 2025

NEW26 new positions
โ†‘25 increased
โ†“19 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023